Sign inCreate account

Report workspace tools

NCT03799848COMPLETEDanonymous

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Hepatic Impairment

Intervention

Source record

Vadadustat

Source & freshness

Source record

NCT ID

NCT03799848

Original source

ClinicalTrials.gov

Source last updated

Mar 22, 2019

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03799848

Title

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 1

Condition raw

Hepatic Impairment

Condition normalized

Hepatic Impairment

Modality raw

Hepatic Impairment

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat

Public preview

Source record

This Phase 1 clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetic profile of a single oral dose of vadadustat in subjects with varying degrees of hepatic function. The study aimed to assess safety and tolerability in a controlled setting.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03799848

Status

COMPLETED

Phase

Phase 1

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

This Phase 1 clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetic profile of a single oral dose of vadadustat in subjects with varying degrees of hepatic function. The study aimed to assess safety and tolerability in a controlled setting.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 22, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03799848

Indication

Hepatic Impairment

Modality

small molecule

Target

Vadadustat

Intervention

Vadadustat

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.